Medtech 360

May 2013

Global Competitor Insights for Facial Injectables 2013

Introduction:

Although Allergan continues to dominate the global facial injectable market, the company is facing increasing competition in both the BTX and dermal filler segments, especially as companies merge and enter into more partnership and distribution agreements.

This Medtech 360 Report provides comprehensive data and analysis on the top ten manufacturers in the global facial injectable market.

We have up-to-date reports on a wide range of medical device markets worldwide.

Questions Answered in This Report:

  *   Allergan continued to dominate the global BTX market with its BOTOX Cosmetic product, which enjoys strong brand loyalty and recognition due to its longstanding monopoly in the market.

How much of a threat does Ipsen's Dysport pose in the global BTX market?

How did the 2012 US injunction against Merz Pharma affect BTX competitors, and what impact is XEOMIN anticipated to have in 2013?

How are competitive dynamics unique in the Asia Pacific BTX market, where local competitors Medytox, LIBP, and Hugel have strong shares?

  *   The global dermal filler market is more saturated than the global BTX market and is highly competitive.

What are the competitive advantages and disadvantages for leading HA filler manufacturers Allergan (JUVÉDERM), Galderma (Restylane), Anteis (Esthélis), and Laboratoires TEOXANE (TEOSYAL)?

What are the competitive advantages and disadvantages for leading other dermal filler manufacturers Merz Pharma (RADIESSE) and Valeant Pharmaceuticals International (Sculptra Aesthetic)?

  *   Acquisitions and partnership agreements continue to change the face of the global facial injectable market.

How did Galderma's acquisition of Q-Med (and therefore its flagship Restylane brand) impact the global HA dermal filler market?

How did Valeant Pharmaceuticals International's acquisition of Sanofi subsidiary Dermik Laboratories impact the global non-HA dermal filler market?

How will Valeant Pharmaceuticals International's recent acquisition of Medicis influence competitive dynamics?

Scope:

Geographies Covered: Our analysis uses the following breakdown of regions:

Region

North America

Country

US

Canada

Europe

Country

France

Germany

Italy

Spain

UK

Asia Pacific

Region

Australasia

Country*

Australia

New Zealand

China

Japan

South Korea

Notes: *Discussed qualitatively only.

Products Covered: Our analysis uses the following breakdown of products in the market:

Product Type

BTX

Dermal Fillers

Material

HA

Other*

Notes: *Other dermal fillers include semipermanent and nonpermanent dermal fillers. Newer-generation PRP and collagen fillers are not included in market valuations for Europe and the Asia Pacific because these new products have yet to make a substantial impact on the market. Other dermal fillers are not considered quantitatively for China or South Korea.

Competitive Analysis: We provide a detailed analysis of the top ten manufacturers in the global facial injectable market in 2012: Allergan, Galderma, Merz Pharma, Ipsen, Anteis, Valeant Pharmaceuticals International, Medytox, LIBP, Laboratoires TEOXANE, and Hugel.

Authors:

Karen Gierszewski

Contributors
Carmen Chan
Samuli Heilala, M. Sc.
Veronica Ross



Search Reports

Mentioned in this report:

  • Allergan
  • Anteis
  • Galderma
  • Hugel
  • Ipsen
  • Laboratoires TEOXANE
  • LIBP
  • Medytox
  • Merz Pharma
  • Valeant Pharmaceuticals International
Decision Resources Group brands include: